智通财经APP获悉，科济药业-B(02171)早盘涨近14%，截至发稿，涨12.94%，报11港元，成交额9411.06万港元。
消息面上，科济药业近期宣布，公司自主研发的一款靶向CD19/CD20的通用型CAR-T细胞治疗候选产品KJ-C2219已完成研究者发起的临床试验（IIT）的首例受试者给药。据悉，KJ-C2219基于THANK-uPlus平台开发，计划用于治疗血液恶性肿瘤和自身免疫性疾病，目前正在中国开展一项针对复发/难治性B细胞非霍奇金淋巴瘤（R/RB-NHL）的研究者发起的临床试验。
国元国际此前指出，科济药业是创新研发驱动型生物科技公司，专注于创新CAR-T细胞疗法，通用型CAR-T技术领先，治疗实体瘤CAR-T取得突破，CT041治疗胃癌有望于25年上半年递交NDA。公司已经有上市产品赛恺泽，由华东医药推广，即将放量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.